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A Measure of Reverse Cholesterol Transport
Rather Than HDL FunctionalityIn a recent issue of the Journal, Qi et al. (1) demon-
strated that high-density lipoprotein cholesterol
(HDL-C)/high-density lipoprotein particles (HDL-P)
ratio might predict atherosclerotic risk and might
explain why high plasma HDL-C levels have failed
to avoid ischemic events in some clinical trials.
Although the HDL-C/HDL-P ratio may provide a poor
and indirect metric for reverse cholesterol transport
(RCT), it is important to emphasize that it does not
reﬂect HDL functionality.
HDL-C/HDL-P ratio is a dynamic parameter, which
is determined primarily by the HDL-P turnover,
especially in a cardiovascular disease–free popula-
tion. High plasma HDL-P may thus be the major factor
predicting atherosclerotic risk, irrespective of plasma
HDL-C. High levels of plasma HDL-P may be achieved
either by increasing the synthesis rate of HDL-P or by
decreasing HDL-P catabolism. Under steady-state
conditions, the synthesis rate of a given protein
(such as apoprotein A-I) is equal to its turnover.
Therefore, an increase in HDL-P synthesis would be
more favorable for the overall process of RCT than
would the inhibition of HDL-P catabolism, because in
the latter mechanism, the HDL-P turnover may be
unaffected. Niacin, for instance, may increase plasma
HDL-C, at least in part, by preventing HDL-C from
being removed by the liver and therefore by blocking
HDL-P catabolism (2). This might explain, although
only in part, why the recent niacin trials did not
provide any cardiovascular beneﬁt.
However, any obstruction or limitation of HDL-P
turnover, either as a result of a reduced synthesis or
increased catabolism, may negatively affect RCT, and
thus lead to more tissue cholesterol deposition. This
afﬁrmation is supported by the data of Qi et al. (1)
showing no inverse relationship between HDL-C
levels and the risk of atherosclerosis progression
except for those in the lowest HDL-P subgroups (low
synthesis or high catabolism) (1).Finally, recent evidence also suggests that the
overall HDL-P is not as important as a determinant of
residual cardiovascular risk as the number of HDL-P,
which contain the lysosphingolipid sphingosine-
1-phosphate (S1P) (3). Pharmacological agents that
increase HDL-P levels by increasing its production in
the liver or that improve the functionality of existing
serum HDL-P, by increasing S1P uptake, for instance,
may be more beneﬁcial.*Emmanuel E. Egom, MSc, MD, PhD
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A Measure of Reverse Cholesterol Transport Rather Than
HDL FunctionalityThe main comment from Dr. Emmanuel E. Egom was
that the high-density lipoprotein cholesterol (HDL-C)/
high-density lipoprotein particle (HDL-P) ratio might
provide a poor and indirect metric for reverse
cholesterol transport (RCT) and did not reﬂect HDL
functionality. According to Dr. Egom’s comments,
HDL-P is a better indicator for the risk of atheroscle-
rosis than the HDL-C/HDL-P ratio, which is deter-
mined by HDL-P turnover. In response to Dr. Egom,
whether the HDL-C/HDL-P ratio in a cardiovascular
disease–free population is a poor or good metric for
RCT really needs further study, especially when there
is a lack of a measurable gold standard for the RCT
concept. If the RCT theory is true, we think that both
HDL-C and number of HDL-P, when used as a single
metric or biomarker, may not well reﬂect the func-
tionality of RCT for the following reasons: 1) the main
antiatherogenic function of RCT is to bring excess
